[Intralesional therapy using recombinant interferon alpha 2 B in lesions of the uterine cervix caused by human papilloma virus].

Abstract

A clinical study on 20 patients with uterine cervix Human Papilloma Virus (HPV) lesions treated with intralesional recombinant alpha 2b interferon (3 millions I.U.) three times a week for three weeks where possible, is presented. After one year from treatment, lesions were cured or stabilized in 18 Patients (90%); progression was observed in 2 patients (10%) for which reason traditional surgical therapy was performed.

• Authors: A Germano, G Stellato, G Lombardo, A de Simone, G Semenza
• Journal: Minerva ginecologica (Minerva Ginecol) Vol. 41 Issue 6 Pg. 277-81 (Jun 1989) ISSN: 0026-4784 [Print] Italy
• Vernacular Title: Terapia intralesionale con interferone alfa 2 B ricombinante in lesioni della cervice uterina da human papilloma virus (HPV).
• PMID: 2549455 (Publication Type: Journal Article)

Chemical References

• Interferon Type I
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins

Topics

• Adult
• Aged
• Carcinoma in Situ (etiology, therapy)
• Drug Evaluation
• Female
• Follow-Up Studies
• Humans
• Interferon Type I (administration & dosage)
• Interferon alpha-2
• Interferon-alpha (administration & dosage, therapeutic use)
• Middle Aged
• Papillomaviridae
• Recombinant Proteins
• Tumor Virus Infections (complications)
• Uterine Cervical Neoplasms (etiology, therapy)